Nintx, a São Paulo, Brazil-based biotech company researching and developing treatments for multifactorial diseases using Brazil’s biodiversity, raised US$10M in funding.
Backers included Pitanga, Ecoa Capital and MOV Investimentos. Strategic partners Tiaraju and Adeste also invested. The Series A funds are complemented with a grant of US$ 2.5M by FINEP.
Guilherme Leal and Peter Andersen remained shareholders.
The company intends to use the funds to support its plans for the coming years, which include accelerating the R&D of eight new drug programs, hiring researchers, introducing new technologies, and expanding the laboratory.
Led by Stephani Saverio, who co-founded the company alongside scientists Miller Freitas and Cristiano Guimarães, Nintx develops a new generation of medicines leveraging biodiversity, primarily from Brazil. One of its key innovations is a broader approach to tackling multifactorial diseases, caused by genetic and environmental factors as well as their interactions via the human gut microbiome. Multifactorial diseases include metabolic, immunological, cancer, and brain disorders.
Nintx advances therapies targeting biological pathways directly and indirectly through gut microbiome modulation, both closely linked to the onset or worsening of multifactorial diseases.
FinSMEs
16/12/2024